Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This phase III study is an open-label extension study to be conducted at approximately 36
investigational sites across 3 countries. The study will evaluate the long-term safety and
tolerability of Chronocort in participants aged 16 years and over when used as treatment for
Congenital Adrenal Hyperplasia (CAH).